

Market Committee at its meeting held on August 13, 2002.¹

The Federal Open Market Committee seeks monetary and financial conditions that will foster price stability and promote sustainable growth in output. To further its long-run objectives, the Committee in the immediate future seeks conditions in reserve markets consistent with maintaining the federal funds rate at an average of around 1¾ percent.

By order of the Federal Open Market Committee, September 27, 2002.

Vincent R. Reinhart,

Secretary, Federal Open Market Committee.

[FR Doc. 02-25142 Filed 10-02-02; 8:45 am]

BILLING CODE 6210-01-S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

White House Initiative on Asian Americans and Pacific Islanders President's Advisory Commission; Notice of Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Public Law 92-463), announcement is made of the following National Advisory body scheduled to conduct a public meeting during the month of October 2002.

Name: President's Advisory Commission on Asian Americans and Pacific Islanders (Commission).

Date and Time: October 11, 2002; 12:30 a.m.–5 p.m. HST.

Location: Hawaii State Capitol, State Capitol Auditorium, 415 S. Beretania Street, Honolulu, HI 96813.

The meeting is open to the public.

The President's Advisory Commission on Asian Americans and Pacific Islanders (AAPIs) will conduct a public meeting on October 11, 2002, from 12:30 p.m. to 5 p.m. HST inclusive.

Agenda items will include, but will not be limited to: testimony from community-based organizations and individuals; testimony from federal, state and local agencies; comments from the public; administrative tasks; deadlines; and upcoming events.

The purpose of the Commission is to advise and make recommendations to the President on ways to increase opportunities for and improve the quality of life of approximately thirteen million AAPIs living in the United States and the U.S.-associated Pacific Island jurisdictions, especially those that are the most underserved.

¹ Copies of the Minutes of the Federal Open Market Committee meeting on August 13, 2002, which includes the domestic policy directive issued at the meeting, are available upon request to the Board of Governors of the Federal Reserve System, Washington, DC 20551. The minutes are published in the Federal Reserve Bulletin and in the Board's annual report.

Requests to address the Commission should be made in writing and should include the name, address, telephone number and business or professional affiliation of the interested party. Individuals or groups addressing similar issues are encouraged to combine comments and make their request to address the Commission through a single representative. The allocation of time for remarks may be adjusted to accommodate the level of expressed interest. Written requests should be faxed to (301) 443-0259.

Anyone who has interest in joining any portion of the meeting or who requires additional information about the Commission should contact: Ms. Betty Lam or Mr. Erik F. Wang, Office of the White House Initiative on AAPIs, Parklawn Building, Room 10-42, 5600 Fishers Lane, Rockville, MD 20857, Telephone (301) 443-2492. Anyone who requires special assistance, such as sign language interpretation or other reasonable accommodations, should contact Mr. Wang no later than October 4, 2002.

Dated: September 27, 2002.

Christopher J. McCabe,

Director, Office of Intergovernmental Affairs.

[FR Doc. 02-25118 Filed 10-2-02; 8:45 am]

BILLING CODE 4165-15-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Public Meeting of the President's Council on Bioethics

AGENCY: The President's Council on Bioethics, HHS.

ACTION: Notice.

SUMMARY: The President's Council on Bioethics will hold its seventh meeting, at which it will discuss, among other things, technological enhancements of human memory; the use of assisted reproduction and other technologies (including PGD) to choose the sex of children; and a presentation by Ms. Suzi Leather, chair of the Human Fertilisation and Embryology Authority (HFEA) of the United Kingdom on how the UK regulates infertility clinics and embryo research. The Council may also touch on subjects discussed at past meetings, including human cloning, embryonic stem cells, and the patentability of human organisms.

DATES: The meeting will take place Thursday, October 17, 2002, from 9 a.m. to 6 p.m. ET; and Friday, October 18, 2002, from 8:30 a.m. to 12:15 p.m. ET.

ADDRESSES: Hotel Monaco, 700 F Street, NW., Washington, DC 20004.

Public Comments: The meeting agenda will be posted at <http://www.bioethics.gov>. Members of the public may submit written statements for the Council's records. Please submit statements to Ms. Diane Gianelli, Director of Communications (tel. 202/

296-4669 or e-mail info@bioethics.gov). The public may also express comments during the time set aside for this purpose, beginning at 5:15 p.m. ET, on Thursday, October 17, 2002. Comments will be limited to no more than five minutes per speaker or organization. Please give advance notice of such statements to Ms. Gianelli at the phone number given above, and be sure to include name, affiliation, and a brief description of the topic or nature of the statement.

FOR FURTHER INFORMATION CONTACT:

Diane Gianelli, 202/296-4669, or visit <http://www.bioethics.gov>.

Dated: September 26, 2002.

Dean Clancy,

Executive Director, The President's Council on Bioethics.

[FR Doc. 02-25117 Filed 10-2-02; 8:45 am]

BILLING CODE 4150-24-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of Inspector General

Draft OIG Compliance Program Guidance for Pharmaceutical Manufacturers

AGENCY: Office of Inspector General (OIG), HHS.

ACTION: Notice and comment period.

SUMMARY: This **Federal Register** notice seeks the comments of interested parties on draft compliance guidance developed by the Office of Inspector General (OIG) for the pharmaceutical industry. Through this notice, the OIG is setting forth its general views on the value and fundamental principles of compliance programs for pharmaceutical manufacturers and the specific elements that pharmaceutical manufacturers should consider when developing and implementing an effective compliance program.

DATES: To assure consideration, comments must be delivered to the address provided below by no later than 5 p.m. on December 2, 2002.

ADDRESSES: Please mail or deliver written comments to the following address: Office of Inspector General, Department of Health and Human Services, Attention: OIG-8-CPG, Room 5246, Cohen Building, 330 Independence Avenue, SW., Washington, DC 20201.

We do not accept comments by facsimile (FAX) transmissions. In commenting, please refer to file code OIGB8-CPG. Comments received timely will be available for public inspection as they are received, generally beginning